QuidelOrtho Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

QuidelOrtho wird ein jährliches Gewinn- und Umsatzwachstum von 112% bzw. 1.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 141.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.2% betragen.

Wichtige Informationen

98.9%

Wachstumsrate der Gewinne

98.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	1.3%
Zukünftige Eigenkapitalrendite	5.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

QuidelOrtho: Attractive Valuation Despite Weak Performance

Apr 13

We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt

Apr 08

QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues

Feb 15

QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 13

QuidelOrtho Corporation Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Feb 18

An Intrinsic Calculation For QuidelOrtho Corporation (NASDAQ:QDEL) Suggests It's 47% Undervalued

Nov 25

QuidelOrtho forecasts strong Q3 revenue above estimates, shares rise ~6% after hours

Oct 12

QuidelOrtho: Fundamentals Remain, Upbeat Financials

Sep 14

Improved Earnings Required Before QuidelOrtho Corporation (NASDAQ:QDEL) Shares Find Their Feet

Sep 03

QuidelOrtho announces $300M share repurchase authorization

Aug 17

Robust Earnings May Not Tell The Whole Story For QuidelOrtho (NASDAQ:QDEL)

Aug 13

Quidel Non-GAAP EPS of $2.34 misses by $0.51, revenue of $613.4M misses by $27.21M

Aug 04

QuidelOrtho: Continuing Its Upward Ascent

Jul 08

Calculating The Fair Value Of QuidelOrtho Corporation (NASDAQ:QDEL)

Jun 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:QDEL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,976	53	N/A	N/A	3
12/31/2025	2,830	-1	404	485	6
12/31/2024	2,743	-1,224	223	249	6
3/31/2024	2,863	-1,765	-119	91	N/A
12/31/2023	2,998	-10	71	280	N/A
10/1/2023	3,122	13	147	369	N/A
7/2/2023	3,162	45	109	318	N/A
4/2/2023	3,110	118	389	573	N/A
1/1/2023	3,266	549	744	885	N/A
10/2/2022	3,036	810	926	1,037	N/A
7/3/2022	2,762	1,006	936	1,124	N/A
4/3/2022	2,326	1,006	484	721	N/A
1/2/2022	1,699	704	513	806	N/A
10/3/2021	1,871	883	634	924	N/A
7/4/2021	1,837	900	712	917	N/A
3/31/2021	1,862	948	1,017	1,154	N/A
1/3/2021	1,662	810	565	630	N/A
9/30/2020	1,005	371	194	238	N/A
6/30/2020	655	155	152	181	N/A
3/31/2020	562	88	135	163	N/A
12/31/2019	535	73	107	134	N/A
9/30/2019	515	75	102	130	N/A
6/30/2019	506	69	117	147	N/A
3/31/2019	501	65	102	133	N/A
12/31/2018	522	74	105	136	N/A
9/30/2018	505	37	77	104	N/A
6/30/2018	438	20	44	67	N/A
3/31/2018	373	12	15	34	N/A
12/31/2017	278	-8	N/A	28	N/A
9/30/2017	216	-5	N/A	33	N/A
6/30/2017	214	0	N/A	38	N/A
3/31/2017	215	4	N/A	49	N/A
12/31/2016	192	-14	N/A	12	N/A
9/30/2016	189	-12	N/A	11	N/A
6/30/2016	187	-12	N/A	11	N/A
3/31/2016	183	-14	N/A	-3	N/A
12/31/2015	194	-6	N/A	37	N/A
9/30/2015	206	1	N/A	38	N/A
6/30/2015	201	-4	N/A	42	N/A
3/31/2015	197	-2	N/A	45	N/A
12/31/2014	184	-7	N/A	36	N/A
9/30/2014	169	-13	N/A	19	N/A
6/30/2014	160	-12	N/A	14	N/A
3/31/2014	158	-6	N/A	13	N/A
12/31/2013	177	7	N/A	26	N/A
9/30/2013	179	15	N/A	38	N/A
6/30/2013	179	19	N/A	44	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: QDEL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: QDEL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: QDEL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: QDELDie Einnahmen des Unternehmens (1.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: QDELDie Einnahmen des Unternehmens (1.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: QDELDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.2 %).

QuidelOrtho Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 89%

Price target decreased by 7.0% to US$56.40

Consensus EPS estimates fall by 602%

Consensus EPS estimates have been downgraded.

QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2024

Recent updates

QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation Announces CEO Changes

New major risk - Revenue and earnings growth

QuidelOrtho Corporation to Report Q1, 2024 Results on May 08, 2024

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

QuidelOrtho: Attractive Valuation Despite Weak Performance

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt

Consensus EPS estimates fall by 89%

Price target decreased by 7.0% to US$56.40

QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test

Consensus EPS estimates fall by 602%

QuidelOrtho Corporation Announces CEO Changes

Consensus EPS estimates have been downgraded.

QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Share price stability

Full year 2023 earnings: EPS and revenues miss analyst expectations

QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2024

President exercised options and sold US$509k worth of stock

QuidelOrtho Corporation to Report Q4, 2023 Results on Feb 13, 2024

QuidelOrtho Corporation Provides Revenue Guidance for the Year 2023

QuidelOrtho Corporation Receives 510(K) Clearance for Savanna(R) Multiplex Molecular Platform and Savanna(R) HSV 1+2/VZV PCR Assay

Price target decreased by 7.8% to US$101

QuidelOrtho Corporation Announces Board Changes

Price target decreased by 9.5% to US$110

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

QuidelOrtho Corporation Provides Earnings Guidance for the Year 2023

QuidelOrtho Corporation to Report Q3, 2023 Results on Nov 01, 2023

QuidelOrtho Corporation Receives CLIA Waiver for Sofia 2 SARS Antigen+ FIA

QuidelOrtho Corporation Announces Resignation of Christopher M. Smith from the Board, Effective August 31, 2023

Consensus EPS estimates fall by 31%

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 38% Below Their Intrinsic Value Estimate

Independent Non-Executive Chairman exercised options and sold US$538k worth of stock

QuidelOrtho Corporation Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

President exercised options and sold US$393k worth of stock

QuidelOrtho Corporation Provides Financial Guidance for the Fiscal Year 2023

President exercised options and sold US$341k worth of stock

Consensus forecasts updated

QuidelOrtho Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended January 1, 2023

QuidelOrtho Corporation Announces Health Canada Grants License for Quidel TriageTrue High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction

Investor sentiment deteriorated over the past week

QuidelOrtho Corporation Announces Executive Changes

An Intrinsic Calculation For QuidelOrtho Corporation (NASDAQ:QDEL) Suggests It's 47% Undervalued

General Counsel exercised options and sold US$173k worth of stock

High number of new directors

General Counsel exercised options and sold US$173k worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

President & COO exercised options and sold US$16k worth of stock

Investor sentiment improved over the past week

QuidelOrtho Corporation to Report Q3, 2022 Results on Nov 02, 2022

QuidelOrtho forecasts strong Q3 revenue above estimates, shares rise ~6% after hours

Price target decreased to US$126

President & COO exercised options and sold US$14k worth of stock

QuidelOrtho: Fundamentals Remain, Upbeat Financials

Improved Earnings Required Before QuidelOrtho Corporation (NASDAQ:QDEL) Shares Find Their Feet

QuidelOrtho Corporation (NasdaqGS:QDEL) announces an Equity Buyback for $300 million worth of its shares.

QuidelOrtho announces $300M share repurchase authorization

Robust Earnings May Not Tell The Whole Story For QuidelOrtho (NASDAQ:QDEL)

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Quidel Non-GAAP EPS of $2.34 misses by $0.51, revenue of $613.4M misses by $27.21M

QuidelOrtho Corporation to Report Q2, 2022 Results on Aug 04, 2022